Professor David Reid, from University of Aberdeen, has expressed fears that thousands of postmenopausal women could suffer from broken bones as they are not receiving proper drugs for osteoporosis.
He added that the current guidance from the National Institute for Health and Clinical Excellence (NICE) is very narrow. Professor Reid, who is chair of the National Osteoporosis Society, added that the NICE guidance was cost-driven and needed to be reviewed urgently.
Professor Reid is also on the speaker's bureau for Novartis, which manufactures newer and more expensive drugs. He said that it was impossible for doctors to not prescribe effective drugs and tell patients they must wait for two years to receive them.
"That's not how we work. You can't come to your doctor and say have you got something else for me, and be told come back in two years time," he explained.
A NICE spokesperson clarified on the guidance in existence and said it means that women must be given access to cost-effective treatments.